Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADR Biomedical Holdings's quarterly market cap
declined
from Sep. 2025 (円7,874.50 Mil) to Dec. 2025 (円7,499.52 Mil) and
declined
from Dec. 2025 (円7,499.52 Mil) to Mar. 2026 (円7,267.39 Mil).
ADR Biomedical Holdings's annual market cap
declined
from Mar. 2024 (円8,660.16 Mil) to Mar. 2025 (円7,160.26 Mil) but then
increased
from Mar. 2025 (円7,160.26 Mil) to Mar. 2026 (円7,267.39 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ADR Biomedical Holdings's Enterprise Value for Today is 円6,695.17 Mil.
ADR Biomedical Holdings (TSE:3750) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ADR Biomedical Holdings Market Cap Related Terms
ADR Biomedical Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ADR Biomedical Holdings's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a Market Cap of 円6,821.07 Mil as of Aug. 24, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADR Biomedical Holdings and its competitors. According to the industry distribution chart, ADR Biomedical Holdings ranks #945 out of 1422 companies in the Biotechnology industry, placing it in the top 66.5%.
Is ADR Biomedical Holdings' Market Cap too high?
ADR Biomedical Holdings' current Market Cap is 円6,821.07 Mil. Based on the distribution chart, ADR Biomedical Holdings ranks #945 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADR Biomedical Holdings has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #945 out of 1422 companies for Market Cap. This places ADR Biomedical Holdings in the lower half of its industry. The industry median Market Cap is 122.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 122.31, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 122.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current Market Cap is 円6,821.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.23, compared to a current price of 円764.00 — trading 1847.5% above its estimated fair value. The current Market Cap is 円6,821.07 Mil. ADR Biomedical Holdings' overall GF Score™ is 24/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Market Cap is 円6,821.07 Mil as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円764.00 is trading 1847.5% above its estimated GF Value™ of 円39.23.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Market Cap: 円6,821.07 Mil
GF Value™: 円39.23 vs. price of 円764.00 (1847.5% above fair value)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
24GF Score
Get the complete analysis for TSE:3750
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
